Comparative Pharmacology
Head-to-head clinical analysis: CLOVIQUE versus TICLID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOVIQUE versus TICLID.
CLOVIQUE vs TICLID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLOVIQUE is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), a pro-inflammatory cytokine. By blocking IL-6 from binding to its receptor, it reduces inflammation and immune responses.
Ticlopidine is a thienopyridine ADP receptor antagonist that irreversibly inhibits the P2Y12 receptor on platelets, preventing ADP-induced platelet aggregation.
10 mg orally once daily.
250 mg orally twice daily
None Documented
None Documented
Terminal half-life of 22-30 hours; allows once-daily dosing with steady-state achieved in 5-7 days
Terminal elimination half-life is approximately 30-50 hours (mean ~33 hours), with clinical effects lasting 7-10 days after discontinuation due to irreversible platelet binding.
Renal: 65-75% unchanged; biliary/fecal: 20-25% as metabolites
Primarily hepatic metabolism; 60% renal as metabolites, 23% fecal. Minimal parent drug excreted unchanged.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent